• Please log in or register to access this feature.

Editorial Comment

You have free access to this content

A controversial consensus – comment on article by Broderick et al

  1. J. W. M. van der Meer1,
  2. A. R. Lloyd2

Article first published online: 11 NOV 2011

DOI: 10.1111/j.1365-2796.2011.02468.x

Issue

Journal of Internal Medicine

Journal of Internal Medicine

Volume 271, Issue 1, pages 29–31, January 2012

Additional Information

How to Cite

van der Meer, J. W. M. and Lloyd, A. R. (2012), A controversial consensus – comment on article by Broderick et al. Journal of Internal Medicine, 271: 29–31. doi: 10.1111/j.1365-2796.2011.02468.x

Author Information

  1. 1

    From the Department of Medicine and Nijmegen Institute for Infection, Inflammation and Immunity (N4i) Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  2. 2

    Inflammation and Infection Research Centre, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia

*Jos W. M. van der Meer, Department of Medicine and Nijmegen Institute for Infection, Inflammation and Immunity (N4i) Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. (fax: +31243541734; e-mail: J.vandermeer@AIG.umcn.nl).

Publication History

  1. Issue published online: 16 DEC 2011
  2. Article first published online: 11 NOV 2011
  3. Accepted manuscript online: 11 OCT 2011 12:16PM EST

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (77K)

References

  • 1
    Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011; 270: 327–38.
    Direct Link:
  • 2
    White PD, Goldsmith KA, Johnson AL et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011; 377: 823–36.
  • 3
    Feehan SM. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1831–2.
  • 4
    Giakoumakis J. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1831; author reply 4–5.
  • 5
    Kewley AJ. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1832; author reply 4–5.
  • 6
    Kindlon T. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1833; author reply 4–5.
  • 7
    Mitchell JT Jr. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1831; author reply 4–5.
  • 8
    Shinohara M. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1833–4; author reply 4–5.
  • 9
    Stouten B, Goudsmit EM, Riley N. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1832–3; author reply 4–5.
  • 10
    Vlaeyen JW, Karsdorp P, Gatzounis R, Ranson S, Schrooten M. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1834; author reply -5.
  • 11
    Prins JB, van der Meer JWM, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367: 346–55.
  • 12
    Lombardi VC, Ruscetti FW, Das Gupta J et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326: 585–9.
  • 13
    van Kuppeveld FJ, van der Meer JW. XMRV and CFS-the sad end of a story. Lancet 2011; PMID: 21696817.
  • 14
    Kaiser J. Chronic fatigue syndrome. Studies point to possible contamination in XMRV findings. Science 2011; 331: 17.
  • 15
    van der Meer JWM, Netea MG, Galama JMD, van Kuppeveld FJM. Comment on “Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome”. Science 2010; 328: 825; author reply.
  • 16
    Sudlow C, Macleod M, Al-Shahi Salman R, Stone J. Comment on “Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome”. Science 2010; 328: 825; author reply.
  • 17
    McClure M, Wessely S. Chronic fatigue syndrome and human retrovirus XMRV. BMJ 2010; 340: c1099.
  • 18
    Lloyd A, White P, Wessely S, Sharpe M, Buchwald D. Comment on “Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome”. Science 2010; 328: 825; author reply.
  • 19
    Hue S, Gray ER, Gall A et al. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010; 7: 111.
  • 20
    Erlwein O, Kaye S, McClure MO et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 2010; 5: e8519.
  • 21
    Lloyd AR. Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. Am J Med 1998; 105: 7S–10S.
  • 22
    Kennedy G, Abbot NC, Spence V, Underwood C, Belch JJF. The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. Ann Epidemiol 2004; 14: 95–100.
  • 23
    Jason LA, Helgerson J, Torres-Harding SR, Carrico AW, Taylor RR. Variability in diagnostic criteria for chronic fatigue syndrome may result in substantial differences in patterns of symptoms and disability. Eval Health Prof 2003; 26: 3–22.
  • 24
    Hickie I, Davenport T, Vernon SD et al. Are chronic fatigue and chronic fatigue syndrome valid clinical entities across countries and healthcare settings? Aust N Z J Psychiatry 2009; 43: 25–35.
  • 25
    Lin JM, Brimmer DJ, Maloney EM, Nyarko E, Belue R, Reeves WC. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metr 2009; 7: 18.
  • 26
    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953–9.
  • 27
    Jason LA, Taylor RR, Plioplys S, Stepanek Z, Shlaes J. Evaluating attributions for an illness based upon the name: chronic fatigue syndrome, myalgic encephalopathy and Florence Nightingale disease. Am J Community Psychol 2002; 30: 133–48.
  • 28
    Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003; 55: 79–90.
  • 29
    McKenzie R, O’Fallon A, Dale J et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998; 280: 1061–6.
  • 30
    Baschetti R. Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome. J Clin Endocrinol Metab 1999; 84: 2263–4.
  • 31
    Cleare AJ, Miell J, Heap E et al. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001; 86: 3545–54.
  • 32
    Blockmans D, Persoons P, Van Houdenhove B, Lejeune M, Bobbaers H. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med 2003; 114: 736–41.
  • 33
    Reeves WC, Lloyd A, Vernon SD et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 2003; 3: 25.
  • 34
    de Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JWM, Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage 2005; 26: 777–81.
  • 35
    Cho HJ, Skowera A, Cleare A, Wessely S. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. Curr Opin Psychiatry 2006; 19: 67–73.
  • 36
    Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160: 221–36.
  • 37
    Wilson A, Hickie I, Hadzi-Pavlovic D et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study Aust N Z J Psychiatry 2001; 35: 520–7.
    Direct Link:
View Full Article (HTML) Get PDF (77K)